Exelixis (EXEL) Stock Price
Exelixis Price
Over the last 19 years Exelixis grew revenue by 18.1% annually, reaching 2.32 B USD. Earnings per share have grown at 11.8% per year over the last 14 years. For Exelixis, the net margin of 33.7% is up versus 16.1% a few years ago. The consensus 12-month price target for Exelixis is 52.00 USD, about 11.9% below where the stock trades today. Of 27 analysts, 12 rate the stock a buy — an overall Hold consensus.
Exelixis stock price
Exelixis business model & stock analysis
Frequently asked questions about Exelixis
The business model of Exelixis Inc is focused on the development, commercialization, and discovery of therapies for the treatment of cancer. The company primarily engages in the research and development of small molecule therapies, targeting specific pathways that contribute to the growth and spread of cancer cells. Exelixis Inc aims to bring innovative and effective cancer treatments to patients by leveraging its expertise in drug discovery and development. The company collaborates with various partners, including pharmaceutical companies and research institutions, to advance its pipeline of potential oncology treatments.
Exelixis Inc is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of Exelixis Inc in the market are Bristol-Myers Squibb Co., Merck & Co. Inc., and Pfizer Inc.
Exelixis Inc. is a biotechnology company founded in 1994, headquartered in Alameda, California. The company focuses on the discovery, development, and commercialization of novel therapies to treat cancer and other serious diseases. With a strong emphasis on precision medicine, Exelixis aims to improve patients' lives through targeted therapies. Throughout its history, Exelixis has made significant advancements in drug development and has brought several innovative medicines to market. Notably, the company's flagship product, CABOMETYX® (cabozantinib), has been approved for the treatment of various cancers. Exelixis continues to invest in research and development, collaborating with partners to expand its pipeline and deliver new treatments to patients worldwide.
Exelixis Inc, a renowned biotechnology company, has achieved significant milestones in its journey. Notably, the company secured a major breakthrough with the FDA approval of its flagship product, Cabometyx, for the treatment of advanced renal cell carcinoma. Additionally, Exelixis Inc successfully expanded Cabometyx's indications to include advanced hepatocellular carcinoma, solid tumors, and differentiated thyroid cancer. The company also witnessed positive clinical trial results, demonstrating the efficacy of Cabometyx in several cancer types. Exelixis Inc's continuous dedication to research and development has propelled it to become a leading name in the pharmaceutical industry, revolutionizing cancer treatment with groundbreaking therapies.
Exelixis Inc is primarily present in the United States, focusing on developing and commercializing innovative medicines. Based in Alameda, California, the company's operations extend across the nation. Exelixis Inc has established strategic partnerships and collaborations worldwide, engaging in research and development efforts with renowned institutions and organizations globally.
Exelixis Inc represents values of innovation, collaboration, and commitment to improving patients' lives. With a focus on discovering and developing small molecule drugs, the company strives for scientific excellence in bringing groundbreaking therapies to market. Exelixis Inc is dedicated to advancing the field of oncology with their portfolio of targeted medicines, addressing the unmet needs of cancer patients. By fostering partnerships and working closely with the medical community, Exelixis Inc believes in the power of collaboration to drive meaningful progress in the fight against cancer.
Analysts currently set an average price target of 51.78 USD for the Exelixis stock (median: 52.00 USD), implying -12.3 % versus the latest price. The consensus is based on 27 analyst ratings.
27 analysts currently rate the Exelixis stock: 12 recommend buying, 14 holding and 1 selling. For 2026, analysts expect Exelixis to generate revenue of 2.55 B USD and earnings per share of 3.51 USD.
Converted at the current exchange rate, the Exelixis share trades at 52.66 EUR (59.02 USD).
The Exelixis share (EXEL) is listed on 8 stock exchanges, including: NASDAQ (EXEL), London (0IJO.L), SIX (Zürich) (EX9.SW), XETRA (EX9.DE), Frankfurt (EX9.F), München (EX9.MU), Düsseldorf (EX9.DU).
Exelixis Inc. is a biopharmaceutical company specializing in the research, development, and marketing of drugs for the treatment of cancer. The company is headquartered in Alameda, California, USA. The business model of Exelixis is based on three pillars: research and development, product marketing and licensing, and collaborations and partnerships with other pharmaceutical companies. Research and development involve the discovery of new compounds and therapies for the treatment of cancer. Exelixis specializes in identifying signaling pathways that are important for the survival and growth of tumor cells. The company has an extensive pipeline of cancer drugs in various stages of development. The most well-known product of Exelixis is Cabozantinib, which is approved for the treatment of kidney cancer and thyroid cancer. Exelixis markets its products through its own sales organization in the USA and through partnerships with other companies worldwide. The company aims to expand its presence in the USA and other countries to increase revenue and profits. Exelixis also works closely with other pharmaceutical companies to acquire licenses for new technologies and products, and to form partnerships for the joint development and marketing of drugs. These collaborations can help accelerate Exelixis' research and development efforts and bring its products to market faster. In summary, the business model of Exelixis Inc. is based on the research, development, and marketing of cancer drugs. The company engages in extensive research and development, has a pipeline of drugs in various stages of development, and collaborates with other companies to acquire new technologies and products and form partnerships for the joint development and marketing of drugs. Exelixis aims to expand its presence in the US and international markets to increase its revenue and profit.
The expected revenue of Exelixis is 2.55 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Exelixis is 988.25 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Exelixis is currently 16.83. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Exelixis stock.
The price-to-sales ratio (P/S) of Exelixis is currently 6.52. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Exelixis stock.
The Eulerpool Quality Score for Exelixis is 6/10.
The ISIN of Exelixis is US30161Q1040. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Exelixis is 936718. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Exelixis is EXEL. The ticker symbol is used to trade Exelixis shares on the stock exchange.
Exelixis stock
Exelixis Peer Group
Exelixis Ticker
Exelixis FIGI
All fundamentals and in-depth analysis of Exelixis
Our stock analysis for Exelixis stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Exelixis. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.